drugset / Trial / NCT01002898
Ritonavir-boosted Lopinavir Monotherapy
Non-randomizedSingle-groupOpen-labelTreatment
Summary
To assess 48-week treatment responses, tolerability, and steady-state minimum plasma concentrations of ritonavir-boosted lopinavir monotherapy for salvage therapy in HIV-1 infected patients who failed antiretroviral regimens containing NRTI and NNRTI.
Timeline
- Start
- 2007-04
- Primary completion
- 2011-02
- Completion
- 2011-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lopinavir | Other / unclassified | 400 mg | — |
| Background | Lamivudine | Other / unclassified | 150 mg | — |
| Background | Ritonavir | Other / unclassified | 100 mg | — |